Moderna should have data available on its Omicron-specific Covid-19 vaccine in March, company CEO Stéphane Bancel said Monday.
“It should be in the clinic in the coming weeks. And we're hoping in the March timeframe, we should be able to have data to share with regulators to figure out the next step forward,” he said in a panel conversation at Davos.
“That’s always been a great partnership between public health experts, the regulators and vaccine makers to figure out what's the best path,” he said.
“For two years, we've all worked literally, you know, seven days a week together to figure out how to fight this common enemy of the virus. The enemy is not another company or another group. The enemy has only been the virus and will stay the virus.”